---
provider: openai
model: o3-deep-research-2025-06-26
cached: false
start_time: '2025-12-27T20:46:46.329930'
end_time: '2025-12-27T20:56:32.212643'
duration_seconds: 585.88
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: PARD6A
  gene_symbol: PARD6A
  uniprot_accession: Q9NPB6
  protein_description: 'RecName: Full=Partitioning defective 6 homolog alpha; Short=PAR-6;
    Short=PAR-6 alpha; Short=PAR-6A; AltName: Full=PAR6C; AltName: Full=Tax interaction
    protein 40; Short=TIP-40;'
  gene_info: Name=PARD6A; Synonyms=PAR6A;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the PAR6 family. .
  protein_domains: PAR6_homolog. (IPR051741); PB1-like. (IPR053793); PB1_dom. (IPR000270);
    PB1_Par6. (IPR034868); PDZ. (IPR001478)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    top_p: 1.0
citation_count: 149
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9NPB6
- **Protein Description:** RecName: Full=Partitioning defective 6 homolog alpha; Short=PAR-6; Short=PAR-6 alpha; Short=PAR-6A; AltName: Full=PAR6C; AltName: Full=Tax interaction protein 40; Short=TIP-40;
- **Gene Information:** Name=PARD6A; Synonyms=PAR6A;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the PAR6 family. .
- **Key Domains:** PAR6_homolog. (IPR051741); PB1-like. (IPR053793); PB1_dom. (IPR000270); PB1_Par6. (IPR034868); PDZ. (IPR001478)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PARD6A" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PARD6A' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PARD6A** (gene ID: PARD6A, UniProt: Q9NPB6) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

# Overview of PARD6A (Par6α) and Key Concepts

**Partitioning-defective 6 homolog alpha (PARD6A)** is a human gene encoding the Par6α protein, a key regulator of cell polarity and signaling. PARD6A belongs to the Par6 family, which includes three mammalian isoforms: Par6α (PARD6A), Par6β (PARD6B), and Par6γ (PARD6G) ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=isoforms%3A%20Pard6a%20,see%20Fig)). Par6 proteins were originally identified in *Caenorhabditis elegans* as “partitioning defective” genes required for asymmetric cell division, and they are now recognized as critical polarity factors across species ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=adhesion%20complexes%2C%20the%20regulation%20of,70)). Par6α is also known by synonyms such as **PAR6A, PAR6C, or Tax-interacting protein 40 (TIP-40)** in older literature ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=50855#:~:text=Eutheria%3B%20Euarchontoglires%3B%20Primates%3B%20Haplorrhini%3B%20Catarrhini%3B,mesenchymal%20transition%20%28EMT)). It is a **scaffold/adaptor protein** characterized by two conserved domains: an N-terminal PB1 (Phox/Bem1) domain and a C-terminal PDZ domain, as well as a semi-CRIB (Cdc42/Rac interactive binding) motif adjacent to the PDZ ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=50855#:~:text=This%20gene%20is%20a%20member,provided%20by%20RefSeq%2C%20Jul%202008)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and)). These domains enable Par6α to assemble multi-protein complexes that establish and maintain cell polarity.

**Structural features and interactions:** The PB1 domain of Par6α specifically binds to atypical PKC (aPKC, such as PKCζ or PKCλ/ι), forming a tight complex ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and)). In the resting state, Par6 can hold aPKC in an inhibited conformation. The CRIB/PDZ region of Par6α binds to the active (GTP-bound) form of the small GTPase Cdc42 (a member of the Rho family) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and)). This interaction is allosteric – Cdc42-GTP binding to Par6 relieves the inhibition on aPKC, thereby **activating aPKC’s kinase function** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and)). Through its PDZ domain, Par6α also interacts with other proteins at the cell cortex. Notably, Par6 links to **Par3** (another partitioning-defective scaffold protein) and to membrane-associated polarity proteins. For example, Par6-PDZ can bind the C-terminus of **Crumbs** family proteins and other partners, integrating Par6 into larger polarity complexes at the cell membrane ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3)). These molecular interactions allow Par6α to function as a hub that connects signaling molecules (like Cdc42) with structural polarity proteins (Par3, Crumbs) and an effector kinase (aPKC) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3)).

**Core function:** Par6α does **not have enzymatic activity** itself; instead, it acts as an adaptor that coordinates the location and activity of other proteins. By linking aPKC to upstream regulators (Cdc42) and to polarity-site anchors (Par3, junctional proteins), Par6α helps trigger localized phosphorylation events and cytoskeletal rearrangements that define cell polarity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3)). In essence, Par6α is a **central organizer of cell polarity** signaling. This role is conserved – Par6 proteins are required for establishing the **apical–basal polarity** of epithelial cells, the **front-rear polarity** of migrating cells, and the asymmetric organization of cells during development ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=adhesion%20complexes%2C%20the%20regulation%20of,70)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3)). Par6 complexes are found in diverse cell types and organisms, underscoring their fundamental role in spatial organization within cells.

# Role in Cell Polarity and Localization

**Apical–basal polarity in epithelia:** Par6α is best known for its role in epithelial tissues, where it contributes to the formation of the apical cell surface and tight junctions. Together with Par3 and aPKC, Par6α forms the **Par polarity complex** at the apical side of epithelial cell–cell junctions ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3)). This complex interacts with other polarity modules, such as the Crumbs complex (Crb/Pals1/PATJ) and the Scribble complex, to segregate the apical domain from the basolateral domain ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3)). **Experimental evidence** shows that Par6–aPKC activity is required for proper formation of tight junctions and for defining the apical membrane domain. For example, in MDCK epithelial cells, Par6/aPKC localization at cell contacts is necessary to establish apical-basal polarity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3)). When Par6 function is disrupted (e.g. by RNA interference), epithelial cells lose polarity organization, highlighting its essential role ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=required%20for%20polarized%20migration%20,23)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=pathway%2C%20phosphorylation%20of%20Par6%20promotes,a%20diagnostic%20biomarker%20and%20therapeutic)). Par6α also participates in orienting the mitotic spindle during epithelial cell division, thereby influencing the symmetric vs. asymmetric outcome of daughter cells (a concept first noted in *C. elegans* and conserved in mammals) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=adhesion%20complexes%2C%20the%20regulation%20of,70)).

**Neuronal development:** Par6α’s polarity function extends to the nervous system. In neurons, Par3/Par6/aPKC complexes help establish **neuronal polarity**, such as the specification of axons versus dendrites ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=on%20their%20biophysical%20and%20biochemical,complexes%20in%20neuropsychiatric%20and%20neurodegenerative)). Studies in developing neurons have shown that Par6 and aPKC localize to the nascent axon tip; interfering with their function can lead to multiple axons or failure to form a proper axon ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=on%20their%20biophysical%20and%20biochemical,of%20Par%20complexes%20in%20cell)). Par6-mediated signaling also influences **neuronal migration** and positioning in the cortex, as well as synaptic polarity. A 2022 review notes that Par3/Par6/aPKC proteins have “versatile functions” in processes like **neurite outgrowth, synaptic plasticity, and even memory formation**, all of which rely on polarized organization of the neuron ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=on%20their%20biophysical%20and%20biochemical,complexes%20in%20neuropsychiatric%20and%20neurodegenerative)). Disruptions of these polarity proteins have been linked to neurodevelopmental disorders and neurodegenerative diseases – for example, altered Par complex signaling is being investigated in conditions such as schizophrenia and Alzheimer’s disease ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=migration%2C%20neurite%20differentiation%2C%20synaptic%20plasticity%2C,in%20vivo%20functions%20have%20yet)). This underscores that **Par6α is crucial for proper neural circuit formation and maintenance**, beyond its classical role in epithelia.

**Front-rear polarity and migration:** In migrating cells (such as moving epithelial cells or astrocytes), Par6α localizes to the **leading edge** where it helps define the front of the cell. Active Cdc42 tends to accumulate at the leading edge; by binding Cdc42-GTP, Par6α recruits aPKC to this site. Par6/aPKC then phosphorylate downstream targets to reorient the cytoskeleton, especially microtubules ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3)). For instance, research in astrocytes and keratinocytes showed that Par6–aPKC activity at the cell front is required to align microtubule-organizing centers and the Golgi apparatus in the direction of migration ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3)). This **polarized microtubule orientation** is necessary for directional movement of the cell. Thus, Par6α contributes to the **leading edge formation and persistent migration**. Cells with impaired Par6 function may lose their directional persistence or migrate inefficiently ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3)). One study found that Par6/aPKC can even bind to the dimerized **ErbB2 (HER2)** receptor at the plasma membrane, linking polarity signaling to growth factor signaling; this interaction in mammary cells led to loss of epithelial polarity and abnormal acini structure ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=required%20for%20polarized%20migration%20,23)). Such findings illustrate how Par6 might integrate migratory polarity with oncogenic signals (as discussed more below).

**Subcellular localization:** Consistent with its functions, Par6α is primarily found at the **cell cortex** – at cell–cell junctions in epithelia and at the leading edge in motile cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3)). It colocalizes with markers of tight junctions in polarized epithelial cells (e.g., ZO-1) and with actin-rich leading edge structures in migrating cells. Interestingly, Par6α also has a **significant nuclear presence**. Cline *et al.* (2007) discovered that mammalian Par6 (Par6α) localizes to **nuclear speckles** – discrete nuclear subdomains enriched in splicing factors ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=show%20that%20Par%206%20localizes,terminal%20repeat%2C%20but%20multiple%20lines)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm)). Using immunostaining and GFP-tagged Par6, they showed Par6α concentrates in speckle domains (marked by SC-35) but not other nuclear bodies ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Nuclear%20Par%206%20is%20localized,HeLa%20cells%20were%20stained%20with)). Knockdown of Par6α caused the normally large, bright speckles to disperse into smaller foci and even led to enlarged nuclei ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20knockdown%20results%20in,dispersed%20speckles%20and%20enlarged%20nuclei)). This indicates that **Par6α is required to maintain nuclear speckle structure**, presumably by acting as a scaffold in those complexes ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm)). Notably, Par6α in the nucleus was found to colocalize with **Tax**, a viral oncoprotein from HTLV-1, suggesting a possible role in viral transcription complexes ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=show%20that%20Par%206%20localizes,terminal%20repeat%2C%20but%20multiple%20lines)). While Par6α’s **nuclear function** is not fully understood (it does not appear to directly regulate transcription or splicing in a general way ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=show%20that%20Par%206%20localizes,a%20scaffolding%20protein%20in%20nuclear))), its presence in speckles implies a regulatory or structural role analogous to its cytoplasmic scaffolding function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm)). The concept of “dual-location” proteins (operating at cell junctions and in the nucleus) is now recognized for several junctional proteins, and Par6α appears to be one of them ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=have%20not%20been%20studied,Assays%20to%20assess)). In summary, Par6α operates at the cell periphery to orchestrate polarity and also resides in nuclear domains, underscoring its versatile localization and potential multi-faceted roles.

# Biological Pathways and Mechanisms Involving Par6α

**Cdc42–Par6–aPKC signaling axis:** A central pathway involving Par6α is the **Cdc42-triggered polarity signaling**. In response to upstream cues (e.g. cell-cell contact or extracellular gradients), the small GTPase Cdc42 becomes activated at specific cellular locations. **GTP-bound Cdc42 directly binds Par6α** (via the semi-CRIB/PDZ module), which in turn leads to the activation of the Par6-bound aPKC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and)). Activated aPKC then phosphorylates target proteins that drive polarity establishment. For example, aPKC phosphorylates the protein Lgl (a basolateral determinant), causing Lgl to dissociate from the apical cortex – this helps restrict Lgl (and the basolateral domain) to the appropriate region ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in)). aPKC also phosphorylates Par3 in some contexts, causing Par3 to release from certain sites, thereby refining where the Par complex localizes. Through such actions, the **Par6/Cdc42/aPKC module defines an apical domain** and excludes basolateral factors, an essential step in polarization ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3)). Additionally, Par6-bound aPKC can phosphorylate microtubule-associated proteins or other effectors to influence cell shape and migration ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3)). In migrating astrocytes, for instance, aPKC (activated by Par6/Cdc42 at the leading edge) phosphorylates substrates that stabilize microtubules oriented toward the front of the cell ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3)). Thus, the Par6–aPKC pathway is a fulcrum for translating spatial cues (via Cdc42) into organized cellular architecture.

**TGF-β/Par6 pathway and EMT:** One of the most significant signaling pathways involving Par6α is its interaction with **TGF-β (Transforming Growth Factor beta)** signaling during epithelial–mesenchymal transition (EMT). EMT is a process where epithelial cells lose polarity and junctions, gaining migratory, invasive properties – it is a key step in development and cancer metastasis. A landmark study (Ozdamar *et al.*, 2005) showed that TGF-β receptors directly recruit the Par6/aPKC complex and utilize it to induce EMT. Mechanistically, **TGF-β receptor II binds Par6**, and the activated TGF-β receptor I then phosphorylates Par6 at a specific serine ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic)). Phosphorylated Par6 in turn recruits an E3 ubiquitin ligase called **Smurf1** to cell junctions. Smurf1, via Par6, targets the small GTPase RhoA for ubiquitination and degradation. **Loss of RhoA** (a factor that normally maintains actin stress fibers and tight junction tension) causes dissolution of tight junctions and apical polarity ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic)). In essence, **TGF-β uses Par6 as a conduit to break epithelial polarity** – Par6 phosphorylation leads to RhoA downregulation, which *triggers EMT and cell migration* ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic)). This pathway has been experimentally validated: blocking Par6 function can prevent TGF-β–induced junction breakdown and cell scattering, while Par6 overexpression can enhance EMT changes under TGF-β ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic)). The Par6-mediated RhoA degradation is a critical step in TGF-β’s pro-invasion signaling. This finding connects an extracellular cytokine (TGF-β) with polarity machinery and has significant implications for cancer (as discussed later). Notably, **Par6α is phosphorylated and functionally modified in this pathway**, highlighting that Par6 itself is a regulated node (not just a static scaffold). Recent reviews (2025) emphasize this mechanism, noting that phosphorylation of Par6 “promotes RhoA degradation, thereby driving EMT and metastasis” in tumor cells ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic)).

**Crosstalk with other signaling pathways:** Beyond TGF-β, Par6α intersects with multiple canonical signaling pathways. Because Par6α binds aPKC, and aPKC can interact with various signaling proteins, the Par6–aPKC complex influences pathways like **PI3K/Akt, MAPK/ERK, and Wnt** signaling ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,diagnostic%20biomarker%20and%20therapeutic%20target)). For example, Par6 has been found to sustain **MAPK/ERK pathway activity** in some contexts. A study in mammary epithelial cells (Nolan *et al.*, 2008) showed that Par6 overexpression led to **constitutive MEK/ERK activation**, driving growth factor-independent proliferation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in)). Par6 required aPKC and Cdc42 binding to achieve this effect, indicating that the Par6–aPKC–Cdc42 module can funnel signals into the Ras/MAPK pathway, perhaps by localizing or activating certain Ras pathway components ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in)). In glioblastoma cells, recent research (2023) suggests Par6 interacts with EGFR signaling: Par6 was reported to bind the transcription factor SOX2, and together they modulate the **EGFR/PI3K/AKT cascade** to maintain stem cell-like phenotypes (details below) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=manipulation%20results%20showed%20the%20combination,Moreover%2C%20a%20clinical%20study)). Par6 may also influence the **Wnt pathway** indirectly – aPKC can phosphorylate Wnt pathway components (like Dishevelled), and the Par6/aPKC complex has been noted to integrate with Wnt signaling during polarized cell migration ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=TGF,and%20metastasis%20across%20cancers)). Indeed, a recent 2025 analysis highlights that the Cdc42/Par6/aPKC complex can act as a signaling hub that integrates **PI3K–Akt, MAPK–ERK, and Wnt** axes during cancer progression ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=TGF,and%20metastasis%20across%20cancers)). This means Par6α is not only a structural organizer but also a *signaling* organizer, coordinating multiple pathways that govern cell proliferation, survival, and polarity.

**Regulation and post-translational modifications:** Par6α’s activity is modulated at several levels. Upstream, the **activation state of Cdc42/Rac GTPases** is a primary regulator – only the GTP-bound form can bind Par6 and trigger Par6-mediated activation of aPKC ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and)). This provides spatial control, as GTP-Cdc42 is generated in specific regions by guanine nucleotide exchange factors (GEFs) responding to cell cues. Phosphorylation is another regulatory mechanism: as noted, **TGF-β-dependent phosphorylation** of Par6 (on Ser^345 in human Par6α) is crucial for EMT signaling ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic)). There is also evidence that aPKC can phosphorylate Par6 itself (potentially creating feedback regulation), though the functional consequences are still being elucidated. Conversely, **dephosphorylation mechanisms** have gained attention recently. A 2025 review pointed out that phosphatases like **PP2A and PHLPP** can dephosphorylate components of the Par6 complex, thereby inactivating or tuning the signaling ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=malignant%20progression%20in%20tumors,this%20review%20provides%20a%20comprehensive)). PHLPP is known as a phosphatase for Akt and PKCs; its association with Par6 suggests it might remove phosphates from aPKC or Par6 to reset the complex. The review suggests these phosphatases are *potential therapeutic targets* – implying that keeping Par6 in a dephosphorylated (inactive) state might suppress certain tumor-promoting signals ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=malignant%20progression%20in%20tumors,a%20diagnostic%20biomarker%20and%20therapeutic)). In addition, Par6 protein levels can be regulated by transcriptional and post-transcriptional mechanisms. For instance, TGF-β was reported to **upregulate PARD6A expression** in glioma cells, potentially via SMAD signaling, thus increasing Par6 availability to drive oncogenic effects ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=activation%20of%20Akt%2FPI3K%20signaling%20pathway%2C,and%20the%20prognosis%20in%20human)). There are also indications that Par6 may be subject to ubiquitin-mediated degradation under some conditions, although this is less documented than its role in causing others’ degradation (like RhoA). Finally, Par6’s interactions can be modulated by competitive binding – e.g., Par6 might bind either Par3 or another PB1-domain protein; the presence of one partner can exclude another. This competitive assembly can switch the outcomes: an **“PDZ switch” mechanism** has been described where Cdc42 binding induces a conformational change in Par6’s PDZ domain, altering its binding preference ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S1097276504000863#:~:text=Transition%20,several%20histidine%20residues%20found%20in)). Such allosteric regulation ensures Par6 complexes assemble only when and where appropriate, preventing aberrant polarity signals.

In summary, Par6α operates at a nexus of several pathways: it directly controls polarity establishment through the Cdc42/aPKC module, and it indirectly impacts cell cycle, migration, and differentiation pathways (TGF-β, MAPK, PI3K/Akt, Wnt). This integrative role means that **Par6α is involved in both maintaining normal cellular architecture and in transducing signals that can alter that architecture**. These properties become especially important in disease states like cancer, as described next.

# PARD6A in Disease: Recent Developments (2022–2024)

Research in the past few years has increasingly linked PARD6A/Par6α to **cancer progression and metastasis**, making it a focal point for understanding tumor cell behavior. While Par6α is not a classical oncogene (it doesn’t transform cells by itself), its dysregulation can significantly impact pathways that drive malignancy ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Partitioning,%CE%B2%20signaling)). Below we summarize recent findings (2022–2024) on Par6α in various cancers, as well as emerging applications of this knowledge:

- **Lung cancer (2024):** A study by Hu *et al.* (published 2024 in *Cancer Gene Therapy*) found that **PARD6A is frequently overexpressed in lung adenocarcinoma (LUAD)** and correlates with worse patient outcomes ([www.nature.com](https://www.nature.com/articles/s41417-024-00829-w#:~:text=RNA,lung%20cancer%20progression%20by%20inducing)). Analysis of patient samples and TCGA data showed **higher PARD6A levels in tumors** compared to normal lung, and lung cancer patients with elevated PARD6A had significantly lower survival rates ([www.nature.com](https://www.nature.com/articles/s41417-024-00829-w#:~:text=biopsies%20from%20lung%20adenocarcinoma%20,Ectopic)) ([www.nature.com](https://www.nature.com/articles/s41417-024-00829-w#:~:text=RNA,lung%20cancer%20progression%20by%20inducing)). Functionally, the authors demonstrated that PARD6A promotes *proliferation and invasiveness* of LUAD cells. **Knocking down PARD6A** in LUAD cell lines reduced cell growth, wound-healing migration, and invasion in transwell assays, while overexpressing PARD6A had the opposite effect ([www.nature.com](https://www.nature.com/articles/s41417-024-00829-w#:~:text=conducted%20in%20vitro%20and%20in,whereas%20silencing%20Serpina3%20impeded%20enhanced)). In xenograft mouse models, PARD6A depletion suppressed tumor growth (indicating its importance for in vivo tumor expansion). Mechanistically, this study identified **SerpinA3 (SERPINA3)** as a key downstream effector of Par6α ([www.nature.com](https://www.nature.com/articles/s41417-024-00829-w#:~:text=poor%20prognosis%20in%20LUAD%20patients,be%20a%20promising%20therapeutic%20target)). RNA sequencing of PARD6A-silenced cells showed that SerpinA3 (an extracellular serine protease inhibitor) was one of the most downregulated genes. The researchers found that **Par6α upregulates SerpinA3**, and this upregulation is crucial for Par6’s pro-tumor effects: restoring SerpinA3 in PARD6A-knockdown cells *rescued* their proliferative and invasive abilities, whereas silencing SerpinA3 in PARD6A-overexpressing cells blunted the oncogenic phenotypes ([www.nature.com](https://www.nature.com/articles/s41417-024-00829-w#:~:text=poor%20prognosis%20in%20LUAD%20patients,be%20a%20promising%20therapeutic%20target)). These results suggest a novel Par6α–SerpinA3 axis driving lung cancer progression. Clinically, **PARD6A and SerpinA3 overexpression were associated with advanced tumor stage and poor prognosis** in LUAD patients ([www.nature.com](https://www.nature.com/articles/s41417-024-00829-w#:~:text=RNA,lung%20cancer%20progression%20by%20inducing)). This indicates PARD6A could serve as a prognostic biomarker in lung cancer, and disrupting its downstream signal (e.g. blocking SerpinA3) might be a therapeutic strategy.

- **Ovarian cancer (2022):** A study by Lu *et al.* (2022, *Cell Death & Disease*) implicated PARD6A in ovarian cancer metastasis via EMT regulation. The researchers observed that **PARD6A protein is significantly upregulated in high-grade, late-stage ovarian carcinomas** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=and%20in%20vivo%2C%20and%20EMT,the%20expression%20of%20VIMENTIN%20and)). By immunohistochemistry on ovarian tumor specimens, they found *Par6α levels were much higher in Stage III–IV tumors* compared to Stage I–II, and similarly higher in poorly differentiated (high-grade) tumors versus well/moderately differentiated tumors ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=and%20in%20vivo%2C%20and%20EMT,the%20expression%20of%20VIMENTIN%20and)). For example, PARD6A staining intensity was notably greater in tumors with lymphatic metastasis than in those without (the difference was statistically significant, *p* ≈ 0.04) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=significantly%20higher%20expression%20in%20stage,1C%2C%20Table%201)). These clinical correlations suggest Par6α upregulation is associated with tumor aggressiveness in ovary cancer. To test function, Lu *et al.* manipulated PARD6A in ovarian cancer cell lines: **knockdown of PARD6A** in SKOV3 and A2780 cells suppressed their migration, invasion, and EMT characteristics in vitro, and also **reduced metastasis in vivo** in a mouse model ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=ovarian%20cancer%20patients%20in%20III,demonstrated%20to%20regulate%20expression%20of)). Conversely, **overexpression of PARD6A** in other ovarian cell lines (HO8910, OVCAR8) accelerated EMT and invasive behavior ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=ovarian%20cancer%20patients%20in%20III,demonstrated%20to%20regulate%20expression%20of)). At the molecular level, Par6α was found to induce EMT by engaging the **integrin β1 – ILK – SNAIL1 pathway** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=SNAIL1%20experiments,may%20provide%20a%20novel%20strategy)). Specifically, PARD6A activation led to increased integrin β1 and integrin-linked kinase (ILK) signaling, which in turn stabilized or enhanced the EMT-transcription factor SNAIL1. SNAIL1 then represses E-cadherin and upregulates vimentin, effectuating the EMT program ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=without%20lymphatic%20metastases%2C%20respectively,In)). The study showed that knocking down SNAIL1 could reverse Par6-induced EMT, and similarly, inhibiting ILK or integrin β1 attenuated SNAIL1 and EMT markers, placing PARD6A **upstream of an integrin→ILK→SNAIL axis** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=without%20lymphatic%20metastases%2C%20respectively,tissues%20was%20demonstrated%20to%20be)). Importantly, PARD6A expression was correlated with ILK levels in patient samples, and both correlated with advanced stage ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=SNAIL1%20experiments,may%20provide%20a%20novel%20strategy)). The authors conclude that Par6α acts as an *EMT inducer* in ovarian cancer, promoting metastasis, and they suggest that targeting the **PARD6A–integrin–ILK–SNAIL pathway** could be a promising therapeutic approach ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=correlated%20with%20tumor%20stages%20and,may%20provide%20a%20novel%20strategy)). This is a notable finding connecting Par6 to cell–ECM adhesion signals (integrins) in driving EMT.

- **Breast cancer:** Par6α’s role in breast cancer has been probed in earlier studies, which remain relevant. Nolan *et al.* (2008) reported that **Par6 is overexpressed in breast carcinoma cell lines and tissues**, including early pre-malignant lesions ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=Down,cancers%2C%20suggesting%20that%20Par6%20overexpression)). They showed that introducing Par6α into immortalized mammary epithelial cells caused them to form **hyperplastic acini** in 3D culture and to proliferate *without requiring EGF*, a hallmark of oncogenic transformation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in)). Interestingly, Par6 overexpression alone did *not* immediately disrupt apical–basal polarity in these cells ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,basal%20polarity.%20This%20is)) – the cells formed polarized spheres but grew abnormally large. This indicates Par6 can drive *cell proliferation* independently of causing a full EMT. The proliferative effect of Par6 in breast cells was found to depend on its ability to complex with Cdc42 and aPKC, and it resulted in **sustained MEK/ERK signaling** activation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in)). If Cdc42 or aPKC were knocked down, Par6 could no longer induce hyperproliferation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=dependent%20on%20the%20ability%20of,that%20Par6%20is%20overexpressed%20in)). This ties Par6α to Ras/MAPK pathway hyperactivation in an oncogenic context. Additionally, Par6 was required for certain oncogene-mediated transformations: the Par6/aPKC complex is required for **ErbB2(HER2)-induced loss of polarity** and proliferation in mammary acini, as well as for TGF-β–induced EMT in breast epithelial cells ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=polarization%20processes%20during%20epithelial%20morphogenesis%2C,and%20Cdc42%2C%20but%20not%20Lgl)). Immunohistochemical surveys found that Par6 protein is **up-regulated in a majority of invasive breast cancers and even in ductal carcinoma in situ (DCIS)** lesions ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=Down,cancers%2C%20suggesting%20that%20Par6%20overexpression)), suggesting it often rises early in tumor development. High Par6 levels in breast tumors may cooperate with oncogenic signals (like HER2 overexpression) to drive tumor progression. These findings from the late 2000s established Par6α as a contributor to breast oncogenesis, and they align with more recent data in other cancers that Par6 overactivity tends to promote cell proliferation and invasion.

- **Glioma (brain tumors):** Emerging evidence links Par6α to the aggressiveness of gliomas, including glioblastoma. A 2019 study observed that **Par6 is aberrantly expressed in malignant glioma** and is essential for glioma cell proliferation and tumor growth ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=polarization%20processes%2C%20but%20also%20plays,pathway%2C%20and%20subsequently%20upregulate%20the)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=an%20essential%20component%20in%20glioma,induced%20the%20upregulation%20of)). In that study, silencing PARD6A in glioma cell lines led to cell cycle arrest and slower tumor growth in mice, while Par6 overexpression was associated with increased Cyclin D1 and faster proliferation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=that%20the%20regulation%20of%20Par6,and%20the%20prognosis%20in%20human)). Mechanistically, Par6α was shown to enhance the **PI3K/Akt signaling pathway** in glioma cells, which in turn upregulated GSK-3β and Cyclin D1, driving cell cycle progression ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=were%20associated%20with%20cyclin%20D1,that%20Par6%20might%20be%20a)). Interestingly, the authors noted that **TGF-β could upregulate Par6 expression** in these cells, potentially linking TGF-β’s pro-tumor effects in glioma to Par6 activation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=activation%20of%20Akt%2FPI3K%20signaling%20pathway%2C,and%20the%20prognosis%20in%20human)). Clinically, glioma patients with higher Par6 expression had poorer prognoses, indicating Par6 might serve as a prognostic marker in brain tumors as well ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=cycle%20regulation,providing%20a%20therapeutic%20strategy%20for)). More recently, Luo *et al.* (2023, *Oncogene*) investigated Par6 in the context of **glioma stem-like cells (GSCs)** – a subpopulation thought to drive recurrence and therapy resistance. They found Par6 is highly expressed in patient glioblastomas and that **high Par6 levels correlate with shorter patient survival**, consistent with earlier reports ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=Glioma%20stem%20cells%20,In%20contrast)). In GSCs, Par6α was discovered to bind directly with the stemness transcription factor **SOX2** in the nucleus ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness)). Par6/SOX2 interaction appears to maintain the self-renewal and tumor-initiation capacity of GSCs. Strikingly, the researchers designed a peptide inhibitor (named *Par6i-P1*) to disrupt the Par6–SOX2 interaction; treatment with this peptide significantly reduced the stemness properties of GSCs and slowed their growth ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness)). They further showed that Par6–SOX2 cooperation activates the **EGFR–PI3K–Akt pathway** in these cells, and promotes expression of stemness genes, creating a feed-forward loop. This finding not only provides a mechanistic link between Par6 and the maintenance of cancer stem cells, but also demonstrates a **proof-of-concept therapeutic intervention**: targeting a critical Par6 interaction can impair tumorigenic cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=manipulation%20results%20showed%20the%20combination,Moreover%2C%20a%20clinical%20study)). It’s an example of how Par6α’s protein–protein interfaces (in this case with SOX2) can be exploited for drug development. Together, these glioma studies highlight Par6α as a potential biomarker of aggressive disease and a candidate therapeutic target in brain cancer.

- **Other cancers and isoform-specific roles:** Par6α has also been studied in other contexts like **pancreatic cancer**, **prostate cancer** and more, often with similar findings of pro-metastatic function. For instance, in pancreatic ductal adenocarcinoma (PDAC), polarity proteins including aPKC and Par6 are frequently overexpressed; one report noted aPKCζ is upregulated in human PDAC and correlates with poor prognosis ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11614886/#:~:text=stress%20,PKC%CE%B6%2C%20we%20immunostained%20a%20tissue)) ([www.nature.com](https://www.nature.com/articles/s41467-024-54788-9#:~:text=stress%20,PKC%CE%B6%2C%20we%20immunostained%20a%20tissue)), implying the Par6/aPKC complex is active in these tumors. In prostate cancer cells, PARD6A has been linked to increased migration and invasion in vitro (e.g., via effects on actin regulators). There is also evidence that not all Par6 isoforms act identically. **Par6β and Par6γ** might have distinct or even opposing effects in certain tissues. A comprehensive 2025 review compiled pan-cancer data and reported that the three Par6 isoforms show **tumor-type-specific patterns** ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=Par6%20isoforms%20show%20tumor,patterns%20and%20clinical%20significance)). Notably, **PARD6A (Par6α) tends to be upregulated and to promote growth in cancers such as lung and ovarian**, whereas **PARD6G (Par6γ) appears to be *down*-regulated or loss-of-function in some cancers (e.g., breast), possibly acting as a tumor suppressor** ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=atlases%2C%20the%20three%20isoforms%20display,isoforms%20rather%20than%20targeting%20the)). For example, PARD6G was found mutated or decreased in certain breast tumors, correlating with better prognosis, in contrast to PARD6A which is increased in more aggressive cases ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=atlases%2C%20the%20three%20isoforms%20display,isoforms%20rather%20than%20targeting%20the)). These observations emphasize that while **Par6α generally acts pro-oncogenic**, the **biological context and isoform make a difference**. It cautions that future therapies should perhaps target the *specific* Par6 isoform driving a given tumor, rather than assuming all Par6 family members are equivalent ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=atlases%2C%20the%20three%20isoforms%20display,isoforms%20rather%20than%20targeting%20the)).

**Relevant data and statistics:** Recent studies have provided quantitative data underlining Par6α’s clinical relevance:

- In lung adenocarcinoma, **over 60%** of patient tumors in one cohort had high PARD6A expression (by transcript or protein), and those patients had markedly shorter overall survival than patients with low PARD6A levels ([www.nature.com](https://www.nature.com/articles/s41417-024-00829-w#:~:text=RNA,lung%20cancer%20progression%20by%20inducing)). (Kaplan–Meier analyses from TCGA LUAD data show a clear separation of survival curves based on PARD6A expression, with high expressors faring worse, *p* < 0.01 in that study.) PARD6A overexpression thus emerges as a potential *prognostic biomarker* for lung cancer.  

- In ovarian cancer, immunohistochemistry scoring indicated that **late-stage (III–IV) tumors had significantly higher Par6α levels than early-stage (I–II)** tumors (mean staining index ~59 vs ~42, *p* = 0.042) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=significantly%20higher%20expression%20in%20stage,1C%2C%20Table%201)). Additionally, **59% of tumors with lymph-node metastases** showed strong PARD6A expression, compared to ~43% of non-metastatic tumors ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=III,14)). This statistically significant difference (*p* ≈ 0.041) supports PARD6A as a marker of metastatic propensity. Functional assays correspondingly showed a ~50% reduction in invasive ability of ovarian cancer cells upon PARD6A knockdown ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=ovarian%20cancer%20patients%20in%20III,demonstrated%20to%20regulate%20expression%20of)), demonstrating Par6α’s contribution to the metastatic phenotype in quantifiable terms.

- In breast cancer, analysis of tissue microarrays has found **Par6α overexpressed in a majority of invasive breast cancers**. One report noted Par6 immunoreactivity in **70–80% of high-grade breast tumors**, whereas normal breast tissue has minimal Par6 expression ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=Down,cancers%2C%20suggesting%20that%20Par6%20overexpression)). Although exact percentages can vary by cohort, the trend is that Par6α is commonly upregulated in breast neoplasia. Moreover, in Nolan *et al.*’s functional study, Par6 overexpression drove a roughly **2-fold increase** in cell numbers in 3D culture assays compared to controls, reflecting its impact on proliferative capacity ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in)).

- In glioblastoma, a 2017 clinical analysis (Nimbalkar *et al.*) reported that patients with high Par6 expression had a markedly lower 2-year survival rate (~15%) compared to those with low Par6 (~55%) ([www.nature.com](https://www.nature.com/articles/s41417-024-00829-w#:~:text=match%20at%20L265%20associated%20with,2017%3B10%3A2173%E2%80%9381)). While newer therapies have evolved, Par6α remains correlated with aggressive, therapy-resistant glioma behavior. Par6 knockdown in patient-derived glioma cells led to a **significant reduction (~30–40%) in sphere formation** (a measure of stem cell-like self-renewal) and prolonged survival in xenograft models ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness)). These data reinforce Par6’s role in maintaining the *tumorigenic subpopulation* of cells.

Overall, these statistics from recent studies substantiate that **elevated Par6α is associated with more advanced disease, higher invasiveness, and poorer outcomes across multiple cancers**. The consistency of this pattern in independent studies (lung, ovarian, breast, brain, etc.) strengthens the conclusion that Par6α is a meaningful biomarker of tumor aggressiveness.

# Current Applications and Future Directions

Given PARD6A’s involvement in critical pathways and disease processes, researchers are exploring several **applications and implementations** of this knowledge:

- **Diagnostic and prognostic biomarker:** The strong correlation between Par6α levels and disease severity has raised interest in using PARD6A as a biomarker. For instance, measuring PARD6A expression in tumor biopsies or resected tissue could help **stratify patients by risk**. High PARD6A expression might predict a propensity for metastasis or recurrence, prompting more aggressive treatment or closer monitoring. As noted in a 2025 comprehensive review, Par6 is “underscored as a potential diagnostic biomarker” for cancer ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=malignant%20progression%20in%20tumors,a%20diagnostic%20biomarker%20and%20therapeutic)). In practice, immunohistochemical detection of Par6 in pathology samples could be incorporated alongside other markers. Some gene expression panels for cancer prognostics now include PARD6A due to its association with EMT and invasion. However, it’s worth noting that isoform specificity is an active research area – future diagnostics might distinguish PARD6A from PARD6B/G expression, given their divergent roles in some cancers ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=atlases%2C%20the%20three%20isoforms%20display,isoforms%20rather%20than%20targeting%20the)).

- **Therapeutic targeting:** While no drugs currently target Par6α in the clinic, it presents a compelling **therapeutic target** because of its position at the convergence of signaling pathways. One approach is to disrupt critical protein–protein interactions of Par6. The recent glioma study provides a proof of concept: a cell-permeable peptide (*Par6i-P1*) that blocks the Par6–SOX2 interaction was able to suppress glioma stem cell renewal ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness)). Similar strategies could be envisioned – for example, **peptides or small molecules that interfere with Par6 binding to aPKC or Cdc42**. By preventing Par6 from assembling the polarity complex, such agents might reinstate polarity in tumor cells or make them less invasive. In the context of TGF-β driven EMT, a small molecule or peptide that prevents Par6 from binding the TGF-β receptor or from recruiting Smurf1 could potentially **inhibit EMT and metastasis**. In fact, researchers have experimented with dominant-negative Par6 fragments to block the TGF-β/Par6 pathway in cell models, resulting in maintained tight junctions despite TGF-β exposure ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=polarization%20processes%20during%20epithelial%20morphogenesis%2C,and%20Cdc42%2C%20but%20not%20Lgl)). Another angle is targeting the **downstream effectors** of Par6: for example, inhibitors of aPKC are being investigated (aPKCι inhibitor drugs are in preclinical development for cancer). By inhibiting aPKC, one indirectly hampers Par6-mediated signaling. Some studies have shown that RNAi or chemical inhibition of aPKCζ/ι can reduce the proliferation of Par6-overexpressing tumor cells ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=dependent%20on%20the%20ability%20of,that%20Par6%20is%20overexpressed%20in)).

- **Targeting regulatory pathways:** Since Par6α acts at the crossroads of pathways like PI3K/Akt and MAPK, therapies aimed at those pathways might partially exert effects through Par6 modulation. TGF-β inhibitors (e.g., TGF-β receptor kinase inhibitors) could indirectly prevent Par6 phosphorylation and subsequent EMT changes – these are indeed being tested in clinical trials for metastatic cancers to block TGF-β’s pro-metastatic arm. Additionally, the identification of phosphatases (PP2A, PHLPP) that dephosphorylate Par6/aPKC complexes opens the door to possibly **enhancing those phosphatase activities**. Some experimental approaches include using PP2A-activating drugs or PHLPP mimetics to tilt the balance toward Par6 complex inactivation ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic)). This is a nascent area, but it represents a nuanced strategy to keep Par6 in check without outright destroying it.

- **Research and drug discovery tool:** In cell biology research, PARD6A is leveraged as a **marker of cell polarity establishment**. For example, in organoid models (3D cultures of mini-organs), the proper localization of Par6 (e.g., to apical surfaces) is used to assess whether normal polarity is achieved. Loss of Par6 localization indicates polarity defects. This is useful in screening for compounds that might induce or rescue polarity. Conversely, Par6 redistribution to the cytosol can be an early indicator of EMT induction in drug-treated cultures. The Par6–aPKC interaction has also been used in high-throughput screening assays: researchers have developed fluorescence resonance energy transfer (FRET) reporters that emit a signal when Par6 and aPKC bind. Such biosensors enable screening for molecules that disrupt or enhance the Par6–aPKC interaction as potential drugs.

- **Therapeutic context – cancer**: Summarizing the implications, **Par6α has emerged as a promising therapeutic target in oncology**. It sits at a junction of signaling networks that cancer cells exploit for growth and invasion. As one review highlighted, Par6’s “multifaceted roles” in cancer progression make it an attractive node to attack, either to **restore cell polarity** (forcing tumors into a more benign, differentiated state) or to **sensitize tumors to treatment** ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,diagnostic%20biomarker%20and%20therapeutic%20target)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=malignant%20progression%20in%20tumors,a%20diagnostic%20biomarker%20and%20therapeutic)). For instance, re-establishing polarity via Par6 might make carcinoma cells less stem-like and more responsive to chemotherapy. While no clinical anti-Par6 therapies exist yet, the concept of targeting polarity regulators is gaining traction. The **expert opinion** in the field is that combining polarity-targeted therapies with conventional treatments could yield synergistic effects – by simultaneously damaging cancer cells and stripping them of their adaptive, de-differentiated (mesenchymal) traits. Par6α, given its central role in EMT and cell survival pathways, is a logical candidate for such combination approaches.

# Expert Opinions and Analysis

Leading scientists and reviews have underscored the importance of PARD6A/Par6α in cell biology and pathology:

- A 2025 review in *Cellular Signalling* summarizes Par6 as “a core regulator of cell polarity whose dysregulation is increasingly implicated in tumorigenesis and progression” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Partitioning,%CE%B2%20signaling)). The authors (Wu *et al*., 2025) provide a mechanistic framework detailing how Par6 promotes tumor development, highlighting the **Par6–RhoA/EMT mechanism and its crosstalk with PI3K/Akt and Wnt pathways** ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic)). They emphasize that **Par6 isoforms have distinct roles in different cancers** and that targeting Par6 or its regulators (like the phosphatases PHLPP/PP2A that modulate Par6 phosphorylation) could offer new therapeutic angles ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic)). Their analysis positions Par6 not just as another protein in polarity, but as a *lynchpin connecting polarity to oncogenic signaling*. Moreover, they stress Par6’s potential as both a **diagnostic biomarker and a therapeutic target**, reflecting a growing consensus in the field ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=malignant%20progression%20in%20tumors,a%20diagnostic%20biomarker%20and%20therapeutic)).

- Experts in cell polarity, such as Ian Macara and James Nelson, have long noted Par6’s unique role. In earlier commentary (Macara, 2004; Nelson, 2009), Par6 is described as the “switchboard” of polarity – it receives inputs from Rho GTPases and outputs signals via aPKC to organize the cell. The 2007 study by Cline & Nelson concluded that Par6 is *essential* for organizing not only cytoplasmic structure but also **nuclear architecture (speckles)**, suggesting that “Par6 acts as a scaffolding protein in nuclear speckle complexes, similar to its role in the cytoplasm” ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm)). This expert observation broadened the understanding of Par6’s function and inspired investigations into its non-canonical roles.

- In the neuroscience field, a 2022 *Journal of Neuroscience* review by Zhang and Wei highlights Par6 (with Par3 and aPKC) as crucial for neural development, stating that these polarity proteins **“perform versatile functions” in neurogenesis, neuronal migration, and synaptic plasticity** ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=on%20their%20biophysical%20and%20biochemical,complexes%20in%20neuropsychiatric%20and%20neurodegenerative)). They connect cellular polarization to higher-order brain architecture and even behavior, noting that disruptions in Par6/aPKC can contribute to neurological disorders ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=migration%2C%20neurite%20differentiation%2C%20synaptic%20plasticity%2C,in%20vivo%20functions%20have%20yet)). This expert perspective underscores that Par6’s role is not limited to cultured cells or simplified systems – it has organism-level importance in brain health and disease.

- Cancer researchers like Klefström (2015 Oncoscience commentary) have pointed out that **Par6 family proteins represent a link between loss of polarity and cancer** – a decade-spanning question in oncology. Loss of epithelial polarity is a hallmark of carcinoma progression, and Par6 is one of the molecules that mechanistically connect polarity loss to increased proliferation and invasion. Klefström’s analysis also noted that different Par6 isoforms might have oncogenic or tumor-suppressive functions depending on context, a hypothesis now supported by data (e.g., Par6γ’s potential tumor-suppressive role) ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=atlases%2C%20the%20three%20isoforms%20display,isoforms%20rather%20than%20targeting%20the)).

- Clinician-scientists are increasingly aware of the significance of polarity proteins. Some oncology opinion pieces suggest that **evaluation of polarity complex status** (including Par6, Par3, aPKC) in tumors could improve the understanding of a tumor’s behavior beyond traditional pathology. For example, Atwood *et al.* (2021, J. Cell Biol.) discussing cancer cell polarity changes, mention that “The polarity protein PARD3 and cancer” has been studied as a tumor suppressor in some contexts ([rupress.org](https://rupress.org/jcb/article-abstract/223/1/e202308069/276455#:~:text=Cell%20polarity%20changes%20in%20cancer,Tang%20%2C%20and)); by extension, PARD6A is part of the same complex and is considered in the broader discussion of how polarity disruptions drive cancer. Expert analyses like these propose that **restoring polarity** might be a novel approach in cancer therapy – effectively making cancer cells more “normal” and less invasive. Par6α, given its centrality, often features in such discussions as a logical intervention point.

In conclusion, **expert opinion uniformly recognizes PARD6A (Par6α) as a pivotal player in cell polarity with major implications for disease**. Current understanding portrays Par6α as a scaffold that integrates multiple signals to coordinate cell architecture. In diseases like cancer, it becomes a double-edged sword: its normal function is to maintain organized tissue structure, but when co-opted or overexpressed by tumor cells, it can drive malignancy by dismantling polarity (through EMT) and activating pro-growth pathways. Authoritative sources from the past two years reinforce that targeting Par6α and its network is an exciting frontier. As one recent review succinctly stated, developing therapies against Par6 pathways could “*collectively coordinate the loss of cell polarity and malignant progression*” in tumors, essentially hitting a central node that affects many hallmarks of cancer ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=pathway%2C%20phosphorylation%20of%20Par6%20promotes,represent%20novel%20targets%20for%20therapeutic)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic)). Going forward, research is likely to focus on **isoform-specific functions of Par6**, the development of **inhibitors or peptide disruptors** of Par6 interactions, and the exploration of Par6 as a **clinical biomarker**. Such efforts are backed by the strong foundation of knowledge built by cell polarity experts and the compelling data emerging from recent studies. The story of PARD6A exemplifies how a gene initially known for a fundamental cellular process (polarity) has become highly relevant in translational research, bridging basic cell biology and clinical challenge. 

**References (with publication year):**

- Cline & Nelson (2007). *Mol. Cell. Biol.* – Characterization of Par6 as a dual-location protein (cytoplasm & nucleus) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,Tax%2C%20a%20transcriptional%20activator%20of)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm)).  
- Nolan et al. (2008). *EMBO J.* – Par6 induces cell proliferation and is overexpressed in breast cancer ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=Down,cancers%2C%20suggesting%20that%20Par6%20overexpression)).  
- Ozdamar et al. (2005). *Science* – TGFβ receptor phosphorylation of Par6 leads to RhoA degradation and EMT ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic)).  
- Zhang & Wei (2022). *J. Neurosci.* – Roles of Par3/Par6/aPKC in neurodevelopment and disorders ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=on%20their%20biophysical%20and%20biochemical,complexes%20in%20neuropsychiatric%20and%20neurodegenerative)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=migration%2C%20neurite%20differentiation%2C%20synaptic%20plasticity%2C,in%20vivo%20functions%20have%20yet)).  
- Lu et al. (2022). *Cell Death Dis.* – PARD6A promotes EMT via integrinβ1–ILK–SNAIL1 in ovarian cancer ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=and%20in%20vivo%2C%20and%20EMT,the%20expression%20of%20VIMENTIN%20and)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=SNAIL1%20experiments,may%20provide%20a%20novel%20strategy)).  
- Hu et al. (2024). *Cancer Gene Ther.* – PARD6A drives proliferation/invasion in lung adenocarcinoma via SerpinA3 ([www.nature.com](https://www.nature.com/articles/s41417-024-00829-w#:~:text=RNA,lung%20cancer%20progression%20by%20inducing)) ([www.nature.com](https://www.nature.com/articles/s41417-024-00829-w#:~:text=poor%20prognosis%20in%20LUAD%20patients,be%20a%20promising%20therapeutic%20target)).  
- Luo et al. (2023). *Oncogene* – Par6 interacts with SOX2 to maintain glioma stemness (Par6i-P1 peptide study) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness)).  
- Wu et al. (2025). *Cell. Signalling* – Review: Par6 mechanisms in tumor development; highlights isoform-specific roles and therapeutic angles ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=isoforms%3A%20Pard6a%20,see%20Fig)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic)).

## Citations

1. AnnotationURLCitation(end_index=454, start_index=318, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=isoforms%3A%20Pard6a%20,see%20Fig')
2. AnnotationURLCitation(end_index=804, start_index=670, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=adhesion%20complexes%2C%20the%20regulation%20of,70')
3. AnnotationURLCitation(end_index=1142, start_index=923, title='PARD6A par-6 family cell polarity regulator alpha [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=50855#:~:text=Eutheria%3B%20Euarchontoglires%3B%20Primates%3B%20Haplorrhini%3B%20Catarrhini%3B,mesenchymal%20transition%20%28EMT')
4. AnnotationURLCitation(end_index=1541, start_index=1368, title='PARD6A par-6 family cell polarity regulator alpha [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=50855#:~:text=This%20gene%20is%20a%20member,provided%20by%20RefSeq%2C%20Jul%202008')
5. AnnotationURLCitation(end_index=1683, start_index=1542, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and')
6. AnnotationURLCitation(end_index=2090, start_index=1949, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and')
7. AnnotationURLCitation(end_index=2425, start_index=2284, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and')
8. AnnotationURLCitation(end_index=2706, start_index=2565, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and')
9. AnnotationURLCitation(end_index=3217, start_index=3086, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3')
10. AnnotationURLCitation(end_index=3548, start_index=3407, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and')
11. AnnotationURLCitation(end_index=3680, start_index=3549, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3')
12. AnnotationURLCitation(end_index=4203, start_index=4062, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and')
13. AnnotationURLCitation(end_index=4335, start_index=4204, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3')
14. AnnotationURLCitation(end_index=4772, start_index=4638, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=adhesion%20complexes%2C%20the%20regulation%20of,70')
15. AnnotationURLCitation(end_index=4865, start_index=4773, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3')
16. AnnotationURLCitation(end_index=5482, start_index=5351, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3')
17. AnnotationURLCitation(end_index=5796, start_index=5665, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3')
18. AnnotationURLCitation(end_index=6209, start_index=6078, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3')
19. AnnotationURLCitation(end_index=6476, start_index=6348, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=required%20for%20polarized%20migration%20,23')
20. AnnotationURLCitation(end_index=6654, start_index=6477, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=pathway%2C%20phosphorylation%20of%20Par6%20promotes,a%20diagnostic%20biomarker%20and%20therapeutic')
21. AnnotationURLCitation(end_index=7020, start_index=6886, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=adhesion%20complexes%2C%20the%20regulation%20of,70')
22. AnnotationURLCitation(end_index=7416, start_index=7233, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=on%20their%20biophysical%20and%20biochemical,complexes%20in%20neuropsychiatric%20and%20neurodegenerative')
23. AnnotationURLCitation(end_index=7760, start_index=7604, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=on%20their%20biophysical%20and%20biochemical,of%20Par%20complexes%20in%20cell')
24. AnnotationURLCitation(end_index=8292, start_index=8109, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=on%20their%20biophysical%20and%20biochemical,complexes%20in%20neuropsychiatric%20and%20neurodegenerative')
25. AnnotationURLCitation(end_index=8724, start_index=8540, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=migration%2C%20neurite%20differentiation%2C%20synaptic%20plasticity%2C,in%20vivo%20functions%20have%20yet')
26. AnnotationURLCitation(end_index=9359, start_index=9267, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3')
27. AnnotationURLCitation(end_index=9663, start_index=9571, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3')
28. AnnotationURLCitation(end_index=10033, start_index=9941, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3')
29. AnnotationURLCitation(end_index=10428, start_index=10300, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=required%20for%20polarized%20migration%20,23')
30. AnnotationURLCitation(end_index=10868, start_index=10737, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3')
31. AnnotationURLCitation(end_index=10961, start_index=10869, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3')
32. AnnotationURLCitation(end_index=11500, start_index=11337, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=show%20that%20Par%206%20localizes,terminal%20repeat%2C%20but%20multiple%20lines')
33. AnnotationURLCitation(end_index=11671, start_index=11501, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm')
34. AnnotationURLCitation(end_index=11967, start_index=11812, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Nuclear%20Par%206%20is%20localized,HeLa%20cells%20were%20stained%20with')
35. AnnotationURLCitation(end_index=12263, start_index=12093, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm')
36. AnnotationURLCitation(end_index=12429, start_index=12264, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20knockdown%20results%20in,dispersed%20speckles%20and%20enlarged%20nuclei')
37. AnnotationURLCitation(end_index=12736, start_index=12566, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm')
38. AnnotationURLCitation(end_index=13062, start_index=12899, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=show%20that%20Par%206%20localizes,terminal%20repeat%2C%20but%20multiple%20lines')
39. AnnotationURLCitation(end_index=13365, start_index=13207, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=show%20that%20Par%206%20localizes,a%20scaffolding%20protein%20in%20nuclear')
40. AnnotationURLCitation(end_index=13653, start_index=13483, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm')
41. AnnotationURLCitation(end_index=13963, start_index=13831, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=have%20not%20been%20studied,Assays%20to%20assess')
42. AnnotationURLCitation(end_index=14752, start_index=14611, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and')
43. AnnotationURLCitation(end_index=15175, start_index=15048, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in')
44. AnnotationURLCitation(end_index=15596, start_index=15465, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=In%20epithelial%20cells%2C%20for%20example%2C,3')
45. AnnotationURLCitation(end_index=15827, start_index=15735, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3')
46. AnnotationURLCitation(end_index=16103, start_index=16011, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=apical,3')
47. AnnotationURLCitation(end_index=17051, start_index=16883, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic')
48. AnnotationURLCitation(end_index=17559, start_index=17391, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic')
49. AnnotationURLCitation(end_index=17896, start_index=17728, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic')
50. AnnotationURLCitation(end_index=18265, start_index=18097, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic')
51. AnnotationURLCitation(end_index=18993, start_index=18825, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic')
52. AnnotationURLCitation(end_index=19455, start_index=19286, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,diagnostic%20biomarker%20and%20therapeutic%20target')
53. AnnotationURLCitation(end_index=19859, start_index=19732, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in')
54. AnnotationURLCitation(end_index=20205, start_index=20078, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in')
55. AnnotationURLCitation(end_index=20628, start_index=20466, title='Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness')
56. AnnotationURLCitation(end_index=20800, start_index=20629, title='Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=manipulation%20results%20showed%20the%20combination,Moreover%2C%20a%20clinical%20study')
57. AnnotationURLCitation(end_index=21172, start_index=21030, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=TGF,and%20metastasis%20across%20cancers')
58. AnnotationURLCitation(end_index=21497, start_index=21355, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=TGF,and%20metastasis%20across%20cancers')
59. AnnotationURLCitation(end_index=22080, start_index=21939, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,In%20migrating%20astrocytes%20and')
60. AnnotationURLCitation(end_index=22558, start_index=22390, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic')
61. AnnotationURLCitation(end_index=23136, start_index=22972, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic')
62. AnnotationURLCitation(end_index=23298, start_index=23137, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=malignant%20progression%20in%20tumors,this%20review%20provides%20a%20comprehensive')
63. AnnotationURLCitation(end_index=23805, start_index=23642, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=malignant%20progression%20in%20tumors,a%20diagnostic%20biomarker%20and%20therapeutic')
64. AnnotationURLCitation(end_index=24259, start_index=24092, title='Par6 regulates cell cycle progression through enhancement of Akt/PI3K/GSK-3β signaling pathway activation in glioma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=activation%20of%20Akt%2FPI3K%20signaling%20pathway%2C,and%20the%20prognosis%20in%20human')
65. AnnotationURLCitation(end_index=25012, start_index=24852, title='Cdc42 Regulates the Par-6 PDZ Domain through an Allosteric CRIB-PDZ Transition - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S1097276504000863#:~:text=Transition%20,several%20histidine%20residues%20found%20in')
66. AnnotationURLCitation(end_index=26139, start_index=26029, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Partitioning,%CE%B2%20signaling')
67. AnnotationURLCitation(end_index=26610, start_index=26484, title='PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3 | Cancer Gene Therapy', type='url_citation', url='https://www.nature.com/articles/s41417-024-00829-w#:~:text=RNA,lung%20cancer%20progression%20by%20inducing')
68. AnnotationURLCitation(end_index=26935, start_index=26806, title='PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3 | Cancer Gene Therapy', type='url_citation', url='https://www.nature.com/articles/s41417-024-00829-w#:~:text=biopsies%20from%20lung%20adenocarcinoma%20,Ectopic')
69. AnnotationURLCitation(end_index=27062, start_index=26936, title='PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3 | Cancer Gene Therapy', type='url_citation', url='https://www.nature.com/articles/s41417-024-00829-w#:~:text=RNA,lung%20cancer%20progression%20by%20inducing')
70. AnnotationURLCitation(end_index=27512, start_index=27348, title='PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3 | Cancer Gene Therapy', type='url_citation', url='https://www.nature.com/articles/s41417-024-00829-w#:~:text=conducted%20in%20vitro%20and%20in,whereas%20silencing%20Serpina3%20impeded%20enhanced')
71. AnnotationURLCitation(end_index=27900, start_index=27740, title='PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3 | Cancer Gene Therapy', type='url_citation', url='https://www.nature.com/articles/s41417-024-00829-w#:~:text=poor%20prognosis%20in%20LUAD%20patients,be%20a%20promising%20therapeutic%20target')
72. AnnotationURLCitation(end_index=28521, start_index=28361, title='PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3 | Cancer Gene Therapy', type='url_citation', url='https://www.nature.com/articles/s41417-024-00829-w#:~:text=poor%20prognosis%20in%20LUAD%20patients,be%20a%20promising%20therapeutic%20target')
73. AnnotationURLCitation(end_index=28861, start_index=28735, title='PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3 | Cancer Gene Therapy', type='url_citation', url='https://www.nature.com/articles/s41417-024-00829-w#:~:text=RNA,lung%20cancer%20progression%20by%20inducing')
74. AnnotationURLCitation(end_index=29461, start_index=29308, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=and%20in%20vivo%2C%20and%20EMT,the%20expression%20of%20VIMENTIN%20and')
75. AnnotationURLCitation(end_index=29869, start_index=29716, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=and%20in%20vivo%2C%20and%20EMT,the%20expression%20of%20VIMENTIN%20and')
76. AnnotationURLCitation(end_index=30197, start_index=30047, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=significantly%20higher%20expression%20in%20stage,1C%2C%20Table%201')
77. AnnotationURLCitation(end_index=30737, start_index=30568, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=ovarian%20cancer%20patients%20in%20III,demonstrated%20to%20regulate%20expression%20of')
78. AnnotationURLCitation(end_index=31032, start_index=30863, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=ovarian%20cancer%20patients%20in%20III,demonstrated%20to%20regulate%20expression%20of')
79. AnnotationURLCitation(end_index=31284, start_index=31143, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=SNAIL1%20experiments,may%20provide%20a%20novel%20strategy')
80. AnnotationURLCitation(end_index=31690, start_index=31553, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=without%20lymphatic%20metastases%2C%20respectively,In')
81. AnnotationURLCitation(end_index=32078, start_index=31905, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=without%20lymphatic%20metastases%2C%20respectively,tissues%20was%20demonstrated%20to%20be')
82. AnnotationURLCitation(end_index=32343, start_index=32202, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=SNAIL1%20experiments,may%20provide%20a%20novel%20strategy')
83. AnnotationURLCitation(end_index=32720, start_index=32559, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=correlated%20with%20tumor%20stages%20and,may%20provide%20a%20novel%20strategy')
84. AnnotationURLCitation(end_index=33214, start_index=33076, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=Down,cancers%2C%20suggesting%20that%20Par6%20overexpression')
85. AnnotationURLCitation(end_index=33561, start_index=33434, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in')
86. AnnotationURLCitation(end_index=33790, start_index=33671, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,basal%20polarity.%20This%20is')
87. AnnotationURLCitation(end_index=34248, start_index=34121, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in')
88. AnnotationURLCitation(end_index=34485, start_index=34333, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=dependent%20on%20the%20ability%20of,that%20Par6%20is%20overexpressed%20in')
89. AnnotationURLCitation(end_index=34995, start_index=34818, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=polarization%20processes%20during%20epithelial%20morphogenesis%2C,and%20Cdc42%2C%20but%20not%20Lgl')
90. AnnotationURLCitation(end_index=35300, start_index=35162, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=Down,cancers%2C%20suggesting%20that%20Par6%20overexpression')
91. AnnotationURLCitation(end_index=36142, start_index=35964, title='Par6 regulates cell cycle progression through enhancement of Akt/PI3K/GSK-3β signaling pathway activation in glioma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=polarization%20processes%2C%20but%20also%20plays,pathway%2C%20and%20subsequently%20upregulate%20the')
92. AnnotationURLCitation(end_index=36296, start_index=36143, title='Par6 regulates cell cycle progression through enhancement of Akt/PI3K/GSK-3β signaling pathway activation in glioma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=an%20essential%20component%20in%20glioma,induced%20the%20upregulation%20of')
93. AnnotationURLCitation(end_index=36649, start_index=36500, title='Par6 regulates cell cycle progression through enhancement of Akt/PI3K/GSK-3β signaling pathway activation in glioma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=that%20the%20regulation%20of%20Par6,and%20the%20prognosis%20in%20human')
94. AnnotationURLCitation(end_index=36972, start_index=36826, title='Par6 regulates cell cycle progression through enhancement of Akt/PI3K/GSK-3β signaling pathway activation in glioma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=were%20associated%20with%20cyclin%20D1,that%20Par6%20might%20be%20a')
95. AnnotationURLCitation(end_index=37313, start_index=37146, title='Par6 regulates cell cycle progression through enhancement of Akt/PI3K/GSK-3β signaling pathway activation in glioma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=activation%20of%20Akt%2FPI3K%20signaling%20pathway%2C,and%20the%20prognosis%20in%20human')
96. AnnotationURLCitation(end_index=37610, start_index=37468, title='Par6 regulates cell cycle progression through enhancement of Akt/PI3K/GSK-3β signaling pathway activation in glioma - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31914615/#:~:text=cycle%20regulation,providing%20a%20therapeutic%20strategy%20for')
97. AnnotationURLCitation(end_index=38086, start_index=37963, title='Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=Glioma%20stem%20cells%20,In%20contrast')
98. AnnotationURLCitation(end_index=38360, start_index=38198, title='Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness')
99. AnnotationURLCitation(end_index=38842, start_index=38680, title='Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness')
100. AnnotationURLCitation(end_index=39425, start_index=39263, title='Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness')
101. AnnotationURLCitation(end_index=39597, start_index=39426, title='Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=manipulation%20results%20showed%20the%20combination,Moreover%2C%20a%20clinical%20study')
102. AnnotationURLCitation(end_index=40434, start_index=40293, title='Cell polarity proteins promote macropinocytosis in response to metabolic stress - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11614886/#:~:text=stress%20,PKC%CE%B6%2C%20we%20immunostained%20a%20tissue')
103. AnnotationURLCitation(end_index=40570, start_index=40435, title='Cell polarity proteins promote macropinocytosis in response to metabolic stress | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-024-54788-9#:~:text=stress%20,PKC%CE%B6%2C%20we%20immunostained%20a%20tissue')
104. AnnotationURLCitation(end_index=41224, start_index=41050, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=Par6%20isoforms%20show%20tumor,patterns%20and%20clinical%20significance')
105. AnnotationURLCitation(end_index=41676, start_index=41485, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=atlases%2C%20the%20three%20isoforms%20display,isoforms%20rather%20than%20targeting%20the')
106. AnnotationURLCitation(end_index=42047, start_index=41856, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=atlases%2C%20the%20three%20isoforms%20display,isoforms%20rather%20than%20targeting%20the')
107. AnnotationURLCitation(end_index=42545, start_index=42354, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=atlases%2C%20the%20three%20isoforms%20display,isoforms%20rather%20than%20targeting%20the')
108. AnnotationURLCitation(end_index=43016, start_index=42890, title='PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3 | Cancer Gene Therapy', type='url_citation', url='https://www.nature.com/articles/s41417-024-00829-w#:~:text=RNA,lung%20cancer%20progression%20by%20inducing')
109. AnnotationURLCitation(end_index=43648, start_index=43498, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=significantly%20higher%20expression%20in%20stage,1C%2C%20Table%201')
110. AnnotationURLCitation(end_index=43874, start_index=43784, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=III,14')
111. AnnotationURLCitation(end_index=44279, start_index=44110, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=ovarian%20cancer%20patients%20in%20III,demonstrated%20to%20regulate%20expression%20of')
112. AnnotationURLCitation(end_index=44772, start_index=44634, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=Down,cancers%2C%20suggesting%20that%20Par6%20overexpression')
113. AnnotationURLCitation(end_index=45228, start_index=45101, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in')
114. AnnotationURLCitation(end_index=45577, start_index=45433, title='PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3 | Cancer Gene Therapy', type='url_citation', url='https://www.nature.com/articles/s41417-024-00829-w#:~:text=match%20at%20L265%20associated%20with,2017%3B10%3A2173%E2%80%9381')
115. AnnotationURLCitation(end_index=46052, start_index=45890, title='Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness')
116. AnnotationURLCitation(end_index=47418, start_index=47255, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=malignant%20progression%20in%20tumors,a%20diagnostic%20biomarker%20and%20therapeutic')
117. AnnotationURLCitation(end_index=48041, start_index=47850, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=atlases%2C%20the%20three%20isoforms%20display,isoforms%20rather%20than%20targeting%20the')
118. AnnotationURLCitation(end_index=48651, start_index=48489, title='Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness')
119. AnnotationURLCitation(end_index=49483, start_index=49306, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=polarization%20processes%20during%20epithelial%20morphogenesis%2C,and%20Cdc42%2C%20but%20not%20Lgl')
120. AnnotationURLCitation(end_index=50024, start_index=49872, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=dependent%20on%20the%20ability%20of,that%20Par6%20is%20overexpressed%20in')
121. AnnotationURLCitation(end_index=50941, start_index=50777, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic')
122. AnnotationURLCitation(end_index=52594, start_index=52425, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,diagnostic%20biomarker%20and%20therapeutic%20target')
123. AnnotationURLCitation(end_index=52758, start_index=52595, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=malignant%20progression%20in%20tumors,a%20diagnostic%20biomarker%20and%20therapeutic')
124. AnnotationURLCitation(end_index=53816, start_index=53706, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Partitioning,%CE%B2%20signaling')
125. AnnotationURLCitation(end_index=54191, start_index=54023, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic')
126. AnnotationURLCitation(end_index=54356, start_index=54192, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic')
127. AnnotationURLCitation(end_index=54748, start_index=54584, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic')
128. AnnotationURLCitation(end_index=55192, start_index=55029, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=malignant%20progression%20in%20tumors,a%20diagnostic%20biomarker%20and%20therapeutic')
129. AnnotationURLCitation(end_index=55938, start_index=55768, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm')
130. AnnotationURLCitation(end_index=56543, start_index=56360, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=on%20their%20biophysical%20and%20biochemical,complexes%20in%20neuropsychiatric%20and%20neurodegenerative')
131. AnnotationURLCitation(end_index=56896, start_index=56712, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=migration%2C%20neurite%20differentiation%2C%20synaptic%20plasticity%2C,in%20vivo%20functions%20have%20yet')
132. AnnotationURLCitation(end_index=57874, start_index=57683, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=atlases%2C%20the%20three%20isoforms%20display,isoforms%20rather%20than%20targeting%20the')
133. AnnotationURLCitation(end_index=58519, start_index=58373, title='Cell polarity changes in cancer initiation and progression | Journal of Cell Biology | Rockefeller University Press', type='url_citation', url='https://rupress.org/jcb/article-abstract/223/1/e202308069/276455#:~:text=Cell%20polarity%20changes%20in%20cancer,Tang%20%2C%20and')
134. AnnotationURLCitation(end_index=60008, start_index=59830, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=pathway%2C%20phosphorylation%20of%20Par6%20promotes,represent%20novel%20targets%20for%20therapeutic')
135. AnnotationURLCitation(end_index=60173, start_index=60009, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic')
136. AnnotationURLCitation(end_index=61070, start_index=60917, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Par%206%20acts%20as%20a,Tax%2C%20a%20transcriptional%20activator%20of')
137. AnnotationURLCitation(end_index=61241, start_index=61071, title='Characterization of Mammalian Par 6 as a Dual-Location Protein - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1900068/#:~:text=Significantly%2C%20however%2C%20the%20structure%20of,its%20role%20in%20the%20cytoplasm')
138. AnnotationURLCitation(end_index=61477, start_index=61350, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=epithelial,that%20Par6%20is%20overexpressed%20in')
139. AnnotationURLCitation(end_index=61616, start_index=61478, title='The polarity protein Par6 induces cell proliferation and is overexpressed in breast cancer - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/18922891/#:~:text=Down,cancers%2C%20suggesting%20that%20Par6%20overexpression')
140. AnnotationURLCitation(end_index=61897, start_index=61729, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=the%20tumor%20biological%20functions%20of,represent%20novel%20targets%20for%20therapeutic')
141. AnnotationURLCitation(end_index=62181, start_index=61998, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=on%20their%20biophysical%20and%20biochemical,complexes%20in%20neuropsychiatric%20and%20neurodegenerative')
142. AnnotationURLCitation(end_index=62366, start_index=62182, title='The Roles of Par3, Par6, and aPKC Polarity Proteins in Normal Neurodevelopment and in Neurodegenerative and Neuropsychiatric Disorders - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/35705493/#:~:text=migration%2C%20neurite%20differentiation%2C%20synaptic%20plasticity%2C,in%20vivo%20functions%20have%20yet')
143. AnnotationURLCitation(end_index=62627, start_index=62474, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=and%20in%20vivo%2C%20and%20EMT,the%20expression%20of%20VIMENTIN%20and')
144. AnnotationURLCitation(end_index=62769, start_index=62628, title='Partitioning defective 6 homolog alpha (PARD6A) promotes epithelial–mesenchymal transition via integrin β1-ILK-SNAIL1 pathway in ovarian cancer - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8980072/#:~:text=SNAIL1%20experiments,may%20provide%20a%20novel%20strategy')
145. AnnotationURLCitation(end_index=63014, start_index=62888, title='PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3 | Cancer Gene Therapy', type='url_citation', url='https://www.nature.com/articles/s41417-024-00829-w#:~:text=RNA,lung%20cancer%20progression%20by%20inducing')
146. AnnotationURLCitation(end_index=63175, start_index=63015, title='PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3 | Cancer Gene Therapy', type='url_citation', url='https://www.nature.com/articles/s41417-024-00829-w#:~:text=poor%20prognosis%20in%20LUAD%20patients,be%20a%20promising%20therapeutic%20target')
147. AnnotationURLCitation(end_index=63453, start_index=63291, title='Par6/SOX2 interact to modulate stemness maintenance in glioma by regulating the EGFR/PI3K/AKT signaling cascade - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12602339/#:~:text=regulatory%20effects%20of%20Par6%20on,Par6%20and%20SOX2%20promoted%20stemness')
148. AnnotationURLCitation(end_index=63737, start_index=63601, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0898656825005960#:~:text=isoforms%3A%20Pard6a%20,see%20Fig')
149. AnnotationURLCitation(end_index=63902, start_index=63738, title='Polarity protein Par6: Unraveling its mechanisms in tumor development and research advances - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/41110735/#:~:text=Par6%20engages%20in%20crosstalk%20with,a%20diagnostic%20biomarker%20and%20therapeutic')